Display options
Cite
Jahnke K, Thiel E, Abrey LE, et al. Diagnosis and management of primary intraocular lymphoma: an update. Clin Ophthalmol. 2007;1(3):247-58
Jahnke, K., Thiel, E., Abrey, L. E., Neuwelt, E. A., & Korfel, A. (2007). Diagnosis and management of primary intraocular lymphoma: an update. Clinical ophthalmology (Auckland, N.Z.), 1(3), 247-58.
Jahnke, Kristoph, et al. "Diagnosis and management of primary intraocular lymphoma: an update." Clinical ophthalmology (Auckland, N.Z.) vol. 1,3 (2007): 247-58.
Jahnke K, Thiel E, Abrey LE, Neuwelt EA, Korfel A. Diagnosis and management of primary intraocular lymphoma: an update. Clin Ophthalmol. 2007 Sep;1(3):247-58. PMID: 19668478; PMCID: PMC2701132.
Copy Download .nbib Format: NLM
Share it on

Clin Ophthalmol. 2007 Sep;1(3):247-58.

Diagnosis and management of primary intraocular lymphoma: an update.

Clinical ophthalmology (Auckland, N.Z.)

Kristoph Jahnke, Eckhard Thiel, Lauren E Abrey, Edward A Neuwelt, Agnieszka Korfel

Affiliations

  1. Department of Hematology, Oncology and Transfusion Medicine, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany. [email protected]

PMID: 19668478 PMCID: PMC2701132

Abstract

Despite recent advances in diagnosis and treatment, the prognosis of primary intraocular lymphoma (PIOL) remains poor, and the optimal treatment has yet to be defined. This review presents an overview of the current status of PIOL with a focus on recent advances in diagnosis and treatment. Recent studies show a decreasing time interval from symptom presentation to diagnosis, likely due to increased awareness of the disease and improved diagnostic tools. Advances in the pathologic characterization of PIOL have been made over the past years, and the development of PIOL animal models can offer the opportunity to study aspects of PIOL pathology, pathogenesis and treatment. Regarding treatment of PIOL, recent larger case series favor the use of systemic chemotherapy plus local ocular treatment as first-line management for patients with concomitant PIOL and PCNSL. For patients with isolated PIOL, the current trend focuses on local first-line treatment and early diagnosis of PIOL. Future studies are needed to confirm these trends. Future directions in the management of PIOL should include studies about pathogenesis, prognostic factors, and treatment optimization. In the future, monoclonal antibodies and radioimmunotherapy could prove useful for PIOL treatment.

Keywords: chemotherapy; diffuse large B-cell lymphoma; non-Hodgkin’s lymphoma; primary central nervous system lymphoma; primary intraocular lymphoma; radiotherapy

References

  1. Clin Cancer Res. 2003 Feb;9(2):711-5 - PubMed
  2. Eye (Lond). 2003 May;17(4):513-21 - PubMed
  3. Semin Ophthalmol. 2006 Jul-Sep;21(3):125-33 - PubMed
  4. J Clin Oncol. 2003 Nov 15;21(22):4151-6 - PubMed
  5. Blood. 2005 Jul 1;106(1):384-5 - PubMed
  6. Ophthalmology. 2001 Mar;108(3):426-7 - PubMed
  7. Ophthalmology. 1999 Sep;106(9):1805-10 - PubMed
  8. J Clin Oncol. 2003 Jan 15;21(2):266-72 - PubMed
  9. Cancer. 2005 Aug 1;104(3):591-7 - PubMed
  10. Ophthalmology. 1999 Dec;106(12):2291-5 - PubMed
  11. J Clin Oncol. 1999 Apr;17(4):1329 - PubMed
  12. Ophthalmology. 2003 Mar;110(3):595-9 - PubMed
  13. Ophthalmology. 2002 Feb;109(2):235-42 - PubMed
  14. Retina. 1995;15(2):125-9 - PubMed
  15. Ophthalmology. 1999 Nov;106(11):2109-20 - PubMed
  16. Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3507-14 - PubMed
  17. Neurosurg Focus. 2006 Nov 15;21(5):E3 - PubMed
  18. Exp Eye Res. 2001 Nov;73(5):581-92 - PubMed
  19. Int J Radiat Oncol Biol Phys. 1992;23(1):9-17 - PubMed
  20. Br J Ophthalmol. 2006 Jun;90(6):690-2 - PubMed
  21. J Clin Oncol. 2006 Aug 20;24(24):3865-70 - PubMed
  22. Exp Eye Res. 2006 May;82(5):760-6 - PubMed
  23. Cancer. 1989 May 15;63(10):1918-21 - PubMed
  24. J Neurooncol. 2002 Jun;58(2):175-8 - PubMed
  25. Ophthalmology. 2002 Sep;109(9):1709-16 - PubMed
  26. Am J Ophthalmol. 1996 Apr;121(4):442-4 - PubMed
  27. J Neurosurg. 1988 Jun;68(6):835-53 - PubMed
  28. J Neurol. 2002 Dec;249(12):1713-6 - PubMed
  29. Ophthalmology. 1998 Sep;105(9):1664-9 - PubMed
  30. Cancer Control. 2004 Sep-Oct;11(5):285-95 - PubMed
  31. Br J Ophthalmol. 1999 Apr;83(4):448-51 - PubMed
  32. Exp Eye Res. 1977;25 Suppl:27-63 - PubMed
  33. Ophthalmology. 2003 Jun;110(6):1241-4 - PubMed
  34. Curr Opin Oncol. 2001 May;13(3):137-42 - PubMed
  35. Ophthalmology. 2003 Feb;110(2):421-6 - PubMed
  36. Surv Ophthalmol. 1979 Mar-Apr;23(5):279-96 - PubMed
  37. Cancer. 1988 Dec 1;62(11):2461-5 - PubMed
  38. Invest Ophthalmol Vis Sci. 2006 Jul;47(7):2750-6 - PubMed
  39. Graefes Arch Clin Exp Ophthalmol. 2004 Nov;242(11):901-13 - PubMed
  40. J Clin Oncol. 2005 Aug 1;23(22):5034-43 - PubMed
  41. Arch Ophthalmol. 1997 Sep;115(9):1152-6 - PubMed
  42. Retina. 2001;21(3):281-4 - PubMed
  43. Lancet. 2003 Jan 25;361(9354):323-31 - PubMed
  44. Surv Ophthalmol. 1975 Jan-Feb;19(4):224-39 - PubMed
  45. Cancer. 2000 Sep 15;89(6):1359-70 - PubMed
  46. Ophthalmology. 2003 Aug;110(8):1671-2 - PubMed
  47. Hematol Oncol Clin North Am. 2005 Aug;19(4):739-49, viii - PubMed
  48. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):3957-64 - PubMed
  49. Leukemia. 2003 Dec;17(12):2257-317 - PubMed
  50. Ocul Immunol Inflamm. 2000 Dec;8(4):243-50 - PubMed
  51. Ophthalmology. 1987 Dec;94(12):1631-9 - PubMed
  52. J Clin Oncol. 2005 Jun 20;23(18):4117-26 - PubMed
  53. Ophthalmology. 1992 Feb;99(2):250-6 - PubMed
  54. Surv Ophthalmol. 2000 May-Jun;44(6):518-26 - PubMed
  55. Invest Ophthalmol Vis Sci. 2003 Dec;44(12):5235-41 - PubMed
  56. Ann Oncol. 2002 Apr;13(4):531-8 - PubMed
  57. Graefes Arch Clin Exp Ophthalmol. 2003 Oct;241(10):860-70 - PubMed
  58. Retina. 1997;17(2):118-23 - PubMed
  59. Blood. 2003 Feb 1;101(3):815-21 - PubMed
  60. Neurosurgery. 2000 Jan;46(1):51-60; discussion 60-1 - PubMed
  61. Cancer. 1996 Mar 1;77(5):827-33 - PubMed
  62. Retina. 1996;16(1):47-56 - PubMed
  63. J Clin Oncol. 1996 Feb;14(2):556-64 - PubMed
  64. Cancer. 1986 Apr 1;57(7):1273-5 - PubMed
  65. Graefes Arch Clin Exp Ophthalmol. 2005 Mar;243(3):189-97 - PubMed
  66. Blood. 2003 Jan 15;101(2):466-8 - PubMed
  67. Ophthalmology. 2001 Feb;108(2):386-99 - PubMed
  68. Eye (Lond). 2007 Sep;21(9):1198-201 - PubMed
  69. Graefes Arch Clin Exp Ophthalmol. 2006 Jun;244(6):663-9 - PubMed
  70. Cancer Control. 1998 Jul;5(4):317-325 - PubMed
  71. Leuk Lymphoma. 2006 Sep;47(9):1800-5 - PubMed
  72. Neurosurgery. 2001 May;48(5):1033-40; discussion 1040-1 - PubMed
  73. J Clin Oncol. 2003 Mar 15;21(6):1044-9 - PubMed
  74. Br J Ophthalmol. 2005 Feb;89(2):238-9 - PubMed
  75. Leuk Lymphoma. 1996 Oct;23(3-4):339-45 - PubMed
  76. J Clin Oncol. 2003 Dec 15;21(24):4489-95 - PubMed
  77. J Neurooncol. 1995;25(1):67-71 - PubMed
  78. J Natl Cancer Inst. 1996 May 15;88(10):675-9 - PubMed
  79. Invest Ophthalmol Vis Sci. 2005 Feb;46(2):415-9 - PubMed
  80. Br J Ophthalmol. 1987 Oct;71(10):748-52 - PubMed
  81. Ocul Immunol Inflamm. 2004 Mar;12(1):7-16 - PubMed
  82. Cancer. 1993 Aug 1;72(3):843-9 - PubMed
  83. Cancer. 2004 Jul 1;101(1):139-45 - PubMed
  84. Ophthalmology. 1988 May;95(5):625-30 - PubMed
  85. Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):559-63 - PubMed
  86. J Clin Oncol. 2001 Feb 1;19(3):742-9 - PubMed
  87. Cancer. 1980 Feb 15;45(4):688-92 - PubMed
  88. Br J Haematol. 2004 Jul;126(2):202-8 - PubMed
  89. J Clin Oncol. 1998 Sep;16(9):3000-6 - PubMed
  90. J Neurooncol. 1999 Jul;43(3):199-201 - PubMed
  91. Clin Adv Hematol Oncol. 2006 Mar;4(3):225-31 - PubMed
  92. Ann Neurol. 2005 Jun;57(6):843-7 - PubMed
  93. Arch Ophthalmol. 1997 Sep;115(9):1157-60 - PubMed
  94. Curr Opin Ophthalmol. 2002 Dec;13(6):411-8 - PubMed
  95. Cancer. 2002 Jul 1;95(1):193-202 - PubMed
  96. Retina. 2002 Feb;22(1):37-43 - PubMed
  97. Oncology. 2001;60(2):134-40 - PubMed
  98. Neurology. 2004 Sep 14;63(5):901-3 - PubMed
  99. Ann Neurol. 2002 Feb;51(2):247-52 - PubMed
  100. J Clin Oncol. 2006 Oct 10;24(29):4754-7 - PubMed
  101. Cancer Res. 2006 Nov 1;66(21):10586-93 - PubMed
  102. Ophthalmology. 2004 Sep;111(9):1762-7 - PubMed
  103. Ann Intern Med. 1993 Dec 1;119(11):1093-104 - PubMed
  104. Graefes Arch Clin Exp Ophthalmol. 2004 Sep;242(9):771-6 - PubMed
  105. J Clin Oncol. 1998 Mar;16(3):859-63 - PubMed
  106. Br J Ophthalmol. 1988 Dec;72(12):905-11 - PubMed
  107. Am J Ophthalmol. 1995 Nov;120(5):671-3 - PubMed
  108. Curr Mol Med. 2001 May;1(2):259-72 - PubMed
  109. J Clin Oncol. 2003 Jun 15;21(12):2407-14 - PubMed
  110. Am J Ophthalmol. 1997 Sep;124(3):362-72 - PubMed
  111. Ophthalmology. 1993 Sep;100(9):1399-406 - PubMed
  112. J Clin Oncol. 2002 Dec 15;20(24):4643-8 - PubMed
  113. Ann Oncol. 2005 Dec;16(12):1974-8 - PubMed
  114. Trans Am Ophthalmol Soc. 2003;101:275-92 - PubMed
  115. Blood. 1999 Apr 15;93(8):2749-51 - PubMed

Publication Types